Anthropic launches Claude Science and its own drug-discovery effort
Anthropic on June 30 introduced Claude Science , a product that adapts its Claude model for scientific laboratories and pharmaceutical research operations. The tool is pitched at analyzing large datasets, reviewing the literature, interpreting biological data, managing computational workflows and generating hypotheses, and it supports analysis and visualization of 3D protein structures used in drug discovery.
The company said Claude is already in use at Novo Nordisk, AstraZeneca and Eli Lilly for tasks such as literature reviews, clinical documentation and regulatory work. Anthropic also said it is standing up its own drug-discovery program aimed at “neglected” diseases that commercial drugmakers tend to skip, and is offering up to 50 research projects as much as $30,000 each in computing credits.
The move pushes Anthropic deeper into enterprise revenue ahead of a widely reported IPO, and into direct competition for the pharma AI market. Anthropic framed the system as a research assistant rather than a replacement for expert judgment, saying AI-generated findings should be independently validated before use in studies or drug development — a caveat that reflects both liability concerns and the unproven track record of AI hypothesis generation at the lab bench.